Bill Maughan
Stock Analyst at Canaccord Genuity
(n/a)
# 4,432
Out of 4,851 analysts
14
Total ratings
12.5%
Success rate
-44.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $26 | $5.07 | +412.82% | 2 | Aug 13, 2024 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $1.83 | +719.67% | 2 | May 10, 2024 | |
| FATE Fate Therapeutics | Maintains: Buy | $11 → $9 | $1.36 | +561.76% | 1 | May 10, 2024 | |
| IMCR Immunocore Holdings | Maintains: Hold | $63 → $67 | $37.77 | +77.39% | 3 | May 9, 2024 | |
| MRNA Moderna | Maintains: Hold | $91 → $106 | $26.22 | +304.27% | 3 | May 3, 2024 | |
| IPSC Century Therapeutics | Maintains: Buy | $22 → $24 | $0.56 | +4,184.95% | 1 | Mar 15, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $60 | $8.47 | +608.38% | 1 | Feb 21, 2024 | |
| MRUS Merus | Initiates: Buy | $45 | $55.99 | -19.63% | 1 | Nov 2, 2023 |
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Buy
Price Target: $26
Current: $5.07
Upside: +412.82%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $1.83
Upside: +719.67%
Fate Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $1.36
Upside: +561.76%
Immunocore Holdings
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $37.77
Upside: +77.39%
Moderna
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $26.22
Upside: +304.27%
Century Therapeutics
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $0.56
Upside: +4,184.95%
Bicycle Therapeutics
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $8.47
Upside: +608.38%
Merus
Nov 2, 2023
Initiates: Buy
Price Target: $45
Current: $55.99
Upside: -19.63%